Getty Images
February 27, 2023 — Amarin Corporation plc announced that data evaluating the role of VASCEPA /VAZKEPA (icosapent ethyl) and eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk patients will be presented at the joint ACC.23 together with the World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA, March 4-6, 2023.
The featured research includes an analysis from the landmark REDUCE-IT trial on the effects of VASCEPA/VAZKEPA (icosapent ethyl) in patients with recent acute coronary syndrome (<12 months before randomization) and an assessment of the mechanistic activity of EPA in cardiovascular event risk reduction.
“We are delighted to share new findings from the REDUCE-IT trial and add to the wealth of data that has consistently validated the utility of icosapent ethyl in treating patient sub-populations at high risk for cardiovascular disease,” said Nabil Abadir, MB. CH.B., Chief Medical Officer and Head of Global Medical Affairs, Amarin. “This important information, coupled with the analysis comparing the antioxidant effects of EPA to docosahexaenoic acid (DHA) or mineral oil and corn oil, should help advance the medical community’s understanding of the role and value of icosapent ethyl and EPA to reduce cardiovascular events in at-risk patients globally.”
Featured Amarin-supported abstracts to be presented at ACC.23/WCC include:
Session 909 – Highlighted Original Research: Ischemic Heart Disease and the Year in Review
Room 219 at 10:21 – 10:30 AM
Sunday, March 5, 2023
Oral presentation
Benefits of Icosapent Ethyl in Patients With Recent Acute Coronary Syndrome (ACS): REDUCE-IT
ACS – presented on behalf of all authors by Phillippe Gabriel Steg
Université Paris – Cite, France
Session 1255 – Valvular Heart Disease: Population Science 2
Poster Hall: Hall F at 10:45 - 11:30 AM
Saturday, March 4, 2023
Poster presentation
Eicosapentaenoic Acid (EPA) Modulated Expression of Proteins Linked to Platelet Activation and Thrombosis in Vascular Endothelial Cells during Inflammation – presented on behalf of all authors by Preston Mason
Department of Medicine, Brigham & Women’s hospital, Harvard Medical School
Session 1691 – Vascular Medicine: Basic and Translational Science 15
Poster Hall: Hall F at 9:45 – 10:30 AM
Monday, March 6, 2023
Poster presentation
Comparing the Effects of Pharmaceutical Grade Mineral Oil, Corn Oil, Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) in a Model of Atherosclerosis In Vitro - presented on behalf of all authors by Preston Mason
Department of Medicine, Brigham & Women’s hospital, Harvard Medical School
Session 1082 – Novel Vascular Pharmacotherapeutics
Pulmonary Vascular Disease, Valvular Heart Disease, Special Topics Moderated Poster Theater 4
Hall F at 10:00 - 10:10 AM
Monday, March 6, 2023
Moderated oral poster presentation
Pharmaceutical Grade Mineral Oil and Corn Oil Do Not Influence Phospholipid Membrane Oxidation Rates Compared to Omega-3 Fatty Acids In Vitro - presented on behalf of all authors by Samuel C.R. Sherratt
Elucida Research, Beverly, MA, USA
For more information: www.vascepa.com
Find more ACC23 conference coverage here
Related Content:
New REDUCE-IT Data Released at ESC Oral Presentation Session
Research Shows Potential to Reduce Major Cardiovascular (CV) Events
Prescription Omega-3 Pill Did Not Affect Outcome for Non-hospitalized Adults With COVID-19
VIDEO: Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study
Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study
January 28, 2026 
